Work

Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD

Year: 2019

Type: article

Abstract: Since 2013, direct-acting antiviral (DAA) drugs have revolutionized the treatment of chronic hepatitis C virus (HCV) infection by offering relatively brief, well-tolerated, and highly effective regimens. At the same time, the United States faces an unprecedented opioid epidemic. With the increase in injection drug use, there have been surges in both HCV infection prevalence and overdose deaths, leading to more HCV-positive deceased kidney donors.1 Individuals with chronic kidney disease (CKD) often have to make the complex decision of whether to undergo early DAA treatment (ie, to reduce the kidney and liver morbidity associated with HCV infection) or to defer treatment in exchange for potentially shorter transplant wait-list times (ie, for an HCV-positive donor kidney).

Source: Kidney Medicine

DOI: 10.1016/j.xkme.2019.07.001

Authors: Meaghan Roche, Deirdre L. Sawinski, Jordana B. Cohen

Institution: University of Pennsylvania

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400